At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
TAK-935 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Part to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies
In Brief
A Phase 2 clinical trial evaluating TAK-935 and Placebo for Developmental and/or Epileptic Encephalopathies. Completed, enrolled 18 participants across 11 sites.
Detailed Summary
The purpose of this study is to characterize the multiple-dose safety and tolerability profile of TAK-935 in adult participants with developmental and/or epileptic encephalopathies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsHealx AI
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartAug 2017
Primary CompletionSep 2018
TodayJul 2026
First PostedMay 25, 2017
Enrollment StartAug 17, 2017
Primary CompletionSep 19, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.1 years ago
Interventions
TAK-935drug
TAK-935 tablets.
Placebodrug
TAK-935 placebo-matching tablets.